Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Yang, Dae Sik | - |
dc.contributor.author | Lee, Jung Ae | - |
dc.contributor.author | Lee, Nam Kwon | - |
dc.contributor.author | Park, Young Je | - |
dc.contributor.author | Kim, Chul Yong | - |
dc.contributor.author | Lee, Nak Woo | - |
dc.contributor.author | Hong, Jin Hwa | - |
dc.contributor.author | Lee, Jae Kwan | - |
dc.contributor.author | Song, Jae Yun | - |
dc.date.accessioned | 2021-12-21T17:41:23Z | - |
dc.date.available | 2021-12-21T17:41:23Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/132434 | - |
dc.description.abstract | Background. Three nomogram models for early stage uterine cervical cancer have been developed (KROG 13-03 for overall survival [OS], SNUH/AMC for disease-free survival[DES], and KROG 12-08 for distant metastases-free survival[DMFS]) after radical hysterectomy (RH) and pelvic lymph node dissection (PLND). This study aimed to validate these models using our cohort with adjuvant radiotherapy. Methods. According to the eligibility criteria of nomogram studies, patients were enrolled in Group A (N = 109) for the two KROG models (RH with PLND and whole pelvic irradiation) and Group B (N = 101) for the SNUH/AMC model (RH with PLND and squamous histology). Using Cox-regression hazard models, the prognostic factors of our cohorts were evaluated. The risk probabilities induced from published nomogram scores were calculated and the concordance indices were evaluated. Results. Group A had 88.1% 5-year OS and 86.0% 5-year DMFS. Group B had 83.0% 5-year DES. In multivariate analyses, large tumor size for OS (HR 8.62, P < 0.001) and DMFS (HR 5.13, P = 0.003), young age (<= 40 versus 41-64 years) for OS (HR 4.63, P = 0.097) and DES (HR 3.44, P = 0.051), and multiple lymph node metastases (0 versus >= 3) for DMFS (HR 4.03, P = 0.031) and DES (HR 3.90, P = 0.038) were significantly correlated. The concordance indices for OS, DMFS, and DES were 0.612 (P = 0.002), 0.597 (P = 0.014), and 0.587 (P = 0.020), respectively: Conclusion. The developed nomogram models after RH and PEND are clinically useful in predicting various types of survival with significance. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI LTD | - |
dc.subject | PELVIC RADIATION-THERAPY | - |
dc.subject | SQUAMOUS-CELL CARCINOMA | - |
dc.subject | RADICAL HYSTERECTOMY | - |
dc.subject | ADENOSQUAMOUS CARCINOMA | - |
dc.subject | PROGNOSTIC-FACTORS | - |
dc.subject | CLINICAL-OUTCOMES | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | STAGE | - |
dc.subject | ADENOCARCINOMA | - |
dc.subject | RADIOTHERAPY | - |
dc.title | Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yang, Dae Sik | - |
dc.contributor.affiliatedAuthor | Lee, Nam Kwon | - |
dc.contributor.affiliatedAuthor | Kim, Chul Yong | - |
dc.contributor.affiliatedAuthor | Lee, Nak Woo | - |
dc.contributor.affiliatedAuthor | Hong, Jin Hwa | - |
dc.contributor.affiliatedAuthor | Lee, Jae Kwan | - |
dc.contributor.affiliatedAuthor | Song, Jae Yun | - |
dc.identifier.doi | 10.1155/2017/2917925 | - |
dc.identifier.wosid | 000400836600001 | - |
dc.identifier.bibliographicCitation | BIOMED RESEARCH INTERNATIONAL, v.2017 | - |
dc.relation.isPartOf | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.title | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.volume | 2017 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | PELVIC RADIATION-THERAPY | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | RADICAL HYSTERECTOMY | - |
dc.subject.keywordPlus | ADENOSQUAMOUS CARCINOMA | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | STAGE | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.